The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.

But there are no hard facts, and a Ligand obligation clouds future licensing economics.

The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.

A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.

But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

Gilead came out swinging in second-line lung cancer, but it might have just whiffed.